Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01706458
Recruitment Status : Completed
First Posted : October 15, 2012
Results First Posted : July 17, 2018
Last Update Posted : June 18, 2021
Information provided by (Responsible Party):
University of Wisconsin, Madison

Brief Summary:
This randomized pilot clinical trial studies sipuleucel-T with or without deoxyribonucleic acid (DNA) vaccine therapy in treating patients with prostate cancer that has not responded to previous treatment with hormones and has spread to other places in the body. Vaccines may help the body build an effective immune response to kill tumor cells. It is not yet known whether giving sipuleucel-T vaccine works better with or without DNA vaccine therapy in treating prostate cancer.

Condition or disease Intervention/treatment Phase
Prostate Cancer Biological: sipuleucel-T Biological: DNA Vaccine Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Trial of Sipuleucel-T, With or Without pTVG-HP DNA Booster Vaccine, in Patients With Castrate-Resistant, Metastatic Prostate Cancer
Actual Study Start Date : May 20, 2013
Actual Primary Completion Date : June 12, 2017
Actual Study Completion Date : August 13, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: sipuleucel-T
Patients receive sipuleucel-T IV on weeks 0, 2, and 4.
Biological: sipuleucel-T
Given IV
Other Name: Provenge

Experimental: sipuleucel-T with DNA Vaccine
Patients receive sipuleucel-T as patients in arm I and pTVG-HP plasmid DNA vaccine ID on weeks 6, 8, 10, and 12, and then at 6 and 9 months.
Biological: sipuleucel-T
Given IV
Other Name: Provenge

Biological: DNA Vaccine
Given ID
Other Name: pTVG-HP with rhGM-CSF

Primary Outcome Measures :
  1. Number of Participants With Immune Response Following Treatment [ Time Frame: 12 months ]
    The primary immunological goal of this study was to determine whether booster immunizations with a DNA vaccine encoding PAP could augment the number of PAP-specific effector and memory T cells following treatment with sipuleucel-T, or prolong the duration of detectable T-cell response. All subjects received a tetanus booster immunization prior to beginning the immunization series, providing a separate test of an individual's immune responsiveness. Responses to PSA, a non-target prostate specific protein, were concurrently evaluated, as were responses to GM-CSF, a component of the PA2024 fusion protein used in the preparation of sipuleucel-T.Samples were evaluated for antigen-specific IFNy or granzyme B secretion by ELISPOT, and the detection of statistically significant antigen-specific responses, that were at least 3-fold over the baseline value, and detectable more than once post-treatment, were used to define immune response to a particular antigen.

Secondary Outcome Measures :
  1. Progression-free Survival [ Time Frame: 12 months ]
    Percentage of patients without radiographic progression at 12 months.

  2. Time to Radiographic Disease Progression [ Time Frame: 12 months ]
    Time to radiographic progression using staging obtained at month 3 as baseline for evaluation.

  3. Measure Prostate-specific Antigen (PSA) Doubling Time [ Time Frame: 12 months ]
    PSA doubling times were calculated from PSA values obtained up to 6 months from day 1 of study treatment. An increase in the PSA doubling time to at least double the baseline value will be defined as a PSA doubling time "response".

Other Outcome Measures:
  1. Overall Survival: Median Time to Death From Any Cause [ Time Frame: up to approximately 5 years ]
    Overall survival is defined as the time interval from randomization to death from any cause or to the last follow-up in censored patients.

  2. Number of Circulating Tumor Cells [ Time Frame: 6 months ]
  3. PAP-specific Antibody and T-cell Immune Responses Following Treatment With Sipuleucel-T and DNA Vaccine [ Time Frame: 12 months ]
    A response resulting from immunization was defined as a PAP-specific response detectable more than once post-treatment that was both significant (compared to media only control), at least 3-fold higher than the pre-treatment value, and with a frequency> 1:100,000 PBMC. An antibody response was defined as any increase in titer over baseline.

  4. Logistic Regression Analysis Will be Conducted to Evaluate Whether PAP-specific Immune Response is Associated With Prolonged (1-year) Progression-free Survival. [ Time Frame: 12 months ]
    Not performed because no progression free survival at one year.

  5. Logistic Regression Analysis Will be Conducted to Evaluate Whether Baseline Immune Responses Predict for Immune Responses Elicited/Augmented Following Treatment With Sipuleucel-T +/- DNA Vaccine. [ Time Frame: 12 months ]
    Not performed because no progression free survival at one year.

  6. The Detection of Antigen Spread to Other Prostate Associated Antigens, and the Identification of Specific Antigens Recognized, Will be Analyzed Descriptively. [ Time Frame: 12 months ]
    Not performed because no progression free survival at one year.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate)
  • Metastatic disease as evidenced by the presence of soft tissue and/or bone metastases on imaging studies (computed tomography [CT] of abdomen/pelvis, bone scintigraphy)
  • Castrate-resistant disease, defined as follows:

    • All patients must have received standard of care androgen deprivation treatment before trial entry (surgical castration versus gonadotropin-releasing hormone [GnRH] analogue or antagonist treatment), and subjects receiving GnRH analogue or antagonist must continue this treatment throughout the time on this study
    • Patients may have been treated previously with a nonsteroidal antiandrogen, with evidence of disease progression subsequently; subjects must be off use of anti-androgen for at least 4 weeks (for flutamide) or 6 weeks (for bicalutamide or nilutamide) prior to registration

      ** Subjects who demonstrate an anti-androgen withdrawal response, defined as a >= 25% decline in PSA within 4-6 week of stopping a nonsteroidal antiandrogen are not eligible until the PSA rises above the nadir observed after antiandrogen withdrawal

    • Castration levels of testosterone (< 50 ng/dL) within 2 weeks of registration
  • Progressive disease while receiving androgen deprivation therapy defined by any one of the following as per the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) bone scan criteria or Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 during or after completing last therapy:

    • PSA: at least two consecutive rises in serum PSA, obtained at a minimum of 1-week intervals, and each value >= 2.0 ng/mL
    • Measurable disease: >= 50% increase in the sum of the cross products of all measurable lesions or the development of new measurable lesions; the short axis of a target lymph node must be at least 15 mm by spiral CT to be considered a target lesion
    • Non-measurable (bone) disease: the appearance of two or more new areas of uptake on bone scan consistent with metastatic disease compared to previous imaging during castration therapy; the increased uptake of pre-existing lesions on bone scan will not be taken to constitute progression, and ambiguous results must be confirmed by other imaging modalities (e.g. X-ray, CT or magnetic resonance imaging [MRI])
  • Must have >= 3 serum PSA values obtained over at least a 12 week period of time prior to registration, including the day of screening, to calculate a PSA doubling time; Note: PSA's are not required to be obtained at the same laboratory; use all PSA values that have been done in last 6 months to calculate PSA doubling time
  • Life expectancy of at least 6 months
  • Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  • White blood cell >= 2000/mm^3
  • Absolute neutrophil count >= 1000/mm^3
  • Hemoglobin (HgB) >= 9.0 mg/dL
  • Platelets >= 100,000/mm^3
  • Creatinine =< 2.0 mg/dL
  • Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
  • Negative serology tests for human immunodeficiency virus (HIV) 1 and 2, and for active hepatitis B or hepatitis C, within 14 days of first peripheral blood collection for sipuleucel-T
  • Patients must be at least 4 weeks from any prior treatments and have recovered (to < grade 2) from acute toxicity attributed to this prior treatment
  • Patients must be informed of the experimental nature of the study and its potential risks, and must sign an Institutional Review Board (IRB)-approved written informed consent form indicating such an understanding

Exclusion Criteria:

  • Small cell or other variant prostate cancer histology
  • Patients may not be receiving other investigational agents or be receiving concurrent anticancer therapy other than androgen deprivation
  • Symptomatic metastatic disease, as defined by the need for opioid analgesics for the treatment of pain attributed to a prostate cancer metastatic lesion; patients receiving opioids must receive approval from the principal investigator (PI) for eligibility
  • Patients may not have been treated with prior sipuleucel-T
  • Treatment with any of the following medications within 28 days of registration, or while on study, is prohibited:

    • Systemic corticosteroids (at doses over the equivalent of 1 mg prednisone daily); inhaled, intranasal or topical corticosteroids are acceptable
    • Prostate cancer (PC)-SPES
    • Saw palmetto
    • Megestrol
    • Ketoconazole
    • 5-alpha-reductase inhibitors-patients already taking 5-alpha-reductase inhibitors prior to 28 days prior to registration may stay on these agents throughout the course of therapy, but these should not be started while patients are on study
    • Diethyl stilbestrol
    • Abiraterone
    • Any other hormonal agent or supplement being used with the intent of cancer treatment
  • External beam radiation therapy within 4 weeks of registration is prohibited, or anticipated need for radiation therapy (e.g. imminent pathological fracture or spinal cord compression) within 3 months of registration
  • Major surgery within 4 weeks of registration is prohibited
  • Prior cytotoxic chemotherapy (e.g. docetaxel, mitoxantrone, cabazitaxel) within 6 months of registration is prohibited
  • Patients with a history of life-threatening autoimmune disease
  • Patients who have undergone splenectomy
  • Patients must not have other active malignancies other than non-melanoma skin cancers or carcinoma in situ of the bladder; subjects with a history of other cancers who have been adequately treated and have been recurrence-free for >= 3 years are eligible
  • Patients with known brain metastases
  • Any antibiotic therapy or evidence of infection within 1 week of registration
  • Any other medical intervention or condition, which, in the opinion of the PI could compromise patient safety or adherence with the study requirements
  • Patients cannot have concurrent enrollment on other phase I, II, or III investigational treatment studies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01706458

Layout table for location information
United States, Wisconsin
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
University of Wisconsin, Madison
Layout table for investigator information
Principal Investigator: Douglas McNeel, M.D., PhD University of Wisconsin, Madison
  Study Documents (Full-Text)

Documents provided by University of Wisconsin, Madison:
Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: University of Wisconsin, Madison Identifier: NCT01706458    
Other Study ID Numbers: CO11816
A534260 ( Other Identifier: UW Madison )
SMPH/MEDICINE/MEDICINE*H ( Other Identifier: UW Madison )
NCI-2012-02026 ( Registry Identifier: NCI Trial ID )
2012-0352 ( Registry Identifier: Institutional Review Board )
First Posted: October 15, 2012    Key Record Dates
Results First Posted: July 17, 2018
Last Update Posted: June 18, 2021
Last Verified: May 2021
Keywords provided by University of Wisconsin, Madison:
Prostate Cancer
Castrate Resistant
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases